Search
1alpha,24S-Dihydroxyvitamin D2
go.drugbank.com/drugs/DB06117ExperimentalLR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol. … It is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity.
Pirlindole
go.drugbank.com/drugs/DB09244ExperimentalPirlindole is a selective, reversible inhibitor of monoamine oxidase (MAO) subtype A (MAO-A) that is approved in several European and non-European countries for the treatment of major depression. … This drug is classified as a reversible inhibitor of monoamine oxidase A enzyme (also known as a RIMA drug). It was developed and is currently used as an antidepressant in Russia.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesPeginterferon alfacon-1
go.drugbank.com/drugs/DB05860Experimental[Infergen] is a bio-engineered type I interferon alpha that is FDA-approved for the treatment of patients with chronic hepatitis C infections. … PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small
Synonyms: PEG INF alfacon-1Formic acid
go.drugbank.com/drugs/DB01942ApprovedInvestigationalIt is commonly used as a preservative and antibacterial agent in livestock feed. … It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings.
Fleroxacin
go.drugbank.com/drugs/DB04576ExperimentalFleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.[A39048]
Categories: Topoisomerase II InhibitorsEdonerpic
go.drugbank.com/drugs/DB05938InvestigationalEdonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.
AZD 3355
go.drugbank.com/drugs/DB05404InvestigationalAZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
Categories: GABA-A Receptor AgonistsProgabide
go.drugbank.com/drugs/DB00837ExperimentalProgabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. … In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these conditions is not fully elucidated
Calanolide A
go.drugbank.com/drugs/DB04886InvestigationalCalanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. … A preliminary dosing study among HIV-infected individuals showed a significant antiviral effect compared with placebo.
Synonyms: Calanolide A, (+)-calanolide AKP-1461
go.drugbank.com/drugs/DB05644InvestigationalKP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue. … Designated a DNA covert nucleoside, the drug consists of a modified base that incorporates randomly into HIV and pairs with multiple bases.